Patents Examined by Venkataraman Balasubramanian
  • Patent number: 10544449
    Abstract: Multi-biotinylated reactants are provided which can be used in divalent complexes for various applications such as colocalization, labeling, immobilization, and purification. Methods for constructing, purifying, and using the bis-biotinylated reactants are also provided. In certain embodiments, two bis-biotinylated reactants are bound to a single streptavidin tetramer to provide a complex having a 1:1 stoichiometry with respect to the bis-biotinylated reactants.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: January 28, 2020
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Gene Shen, Natasha Popovich, Erik Miller, Satwik Kamtekar, Keith Bjornson, Jeremiah Hanes, Stephen Yue, Lubomir Sebo, Zhong Wang
  • Patent number: 10526344
    Abstract: Provided herein are compounds useful for appending amino acids to nucleophiles.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: January 7, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Thomas Nittoli, Srinath Thirumalai Rajan, Thomas P. Markotan, Nareshkumar Jain
  • Patent number: 10526343
    Abstract: Novel heterocyclic fused systems are disclosed herein which possess numerous biological activities, including but not limited to antibacterial activity, and usefulness to the treatment of many disease states, such as pathogenic infections. In particular, new imidazoles are disclosed along with related processes of preparation and methods of use as antibacterial agents. The disclosed compounds were found to be active against several Gram-positive bacteria, including Enterococcus faecalis and Bacillus subtilis, and were also found to be active against several species of multi-drug resistant Staphylococcus, such as S. aureus, S. saprophyticus, S. haemolyticus, and S. epidermidis.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: January 7, 2020
    Assignee: UNIVERSITY OF SHARJAH
    Inventors: Taleb H. Altel, Raafat A El-Awady, Srinivasulu Vunnam, Farah Ibrahim Al-Marzooq
  • Patent number: 10526341
    Abstract: Described herein are thienopyrimidine compounds of Formula (I), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the thienopyrimidine compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., brain tumors such as DIPGs) in a subject. The invention further provides an embryonic stem cell-based tumor cell model, which can be used for drug screening and disease target identification.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: January 7, 2020
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Viviane Tabar, Kosuke Funato
  • Patent number: 10519146
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: December 31, 2019
    Assignee: Amgen Inc.
    Inventors: Brian Alan Lanman, Jian Chen, Anthony B. Reed, Victor J. Cee, Longbin Liu, David John Kopecky, Patricia Lopez, Ryan Paul Wurz, Thomas T. Nguyen, Shon Booker, Nobuko Nishimura, Youngsook Shin, Nuria A. Tamayo, John Gordon Allen, Jennifer Rebecca Allen
  • Patent number: 10519168
    Abstract: Methods of making compounds of Formula I are disclosed:
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: December 31, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: John Enquist, Jr., Nolan Griggs, Christopher Hale, Norihiro Ikemoto, Andrew W. Waltman
  • Patent number: 10519121
    Abstract: Processes are disclosed for making vortioxetine and pharmaceutically acceptable salts thereof. A propylene glycol solvate of vortioxetine hydrobromide is disclosed. A novel crystalline form of vortioxetine hydrobromide propylene glycol solvate, designated form AC1, is disclosed along with a method for making same. Form AC1 may be characterized by an x-ray powder diffraction pattern with peaks at about 19.64, 22.85, 25.51, 29.57, 30.18±0.2 degrees 2-theta.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: December 31, 2019
    Assignee: Apicore US LLC
    Inventors: Ravishanker Kovi, Jayaraman Rao Kannapan, Ananda Babu Thirunavakarasu, Veerabhadra Rao Bobbili, Gaurav Yadav
  • Patent number: 10513509
    Abstract: Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: December 24, 2019
    Assignee: Recurium IP Holdings, LLC
    Inventors: Kevin Duane Bunker, Peter Qinhua Huang, Sunny Abraham, Joseph Robert Pinchman, Chad Daniel Hopkins, Deborah Helen Slee
  • Patent number: 10508118
    Abstract: The present invention relates to a compound of formula I, a stereoisomer, a prodrug, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, and a process for preparing the same, a pharmaceutical composition comprising the same, and use of the compound in the preparation of medicine preventing and treating tumors, wherein the substituents are as defined in the specification.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: December 17, 2019
    Assignee: Xiamen University
    Inventors: Xianming Deng, Zhongji Zhuang, Zhou Deng, Xiaoxing Huang, Yan Liu, Ting Zhang, Wei Huang, Qingyan Xu, Zhiyu Hu
  • Patent number: 10494372
    Abstract: The present invention relates to a novel method of preparing copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride. The present invention also relates to copanlisib dihydrochloride hydrates as compounds.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: December 3, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Jan-Georg Peters, Philipp Rubenbauer, Daniel Götz, Danja Großbach, Franz-Josef Mais, Heiko Schirmer, Juergen Stiehl, Kai Lovis, Andreas Lender, Martin Seyfried, Theodor Zweifel, Maurus Marty, Günter Weingärtner
  • Patent number: 10494373
    Abstract: Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: December 3, 2019
    Assignee: Guangdong Zhongsheng Pharmaceutical Co., Ltd
    Inventors: Charles Z. Ding, Shuhui Chen, Baoping Zhao, Xile Liu, Linxia Xiao, Chao Ding, Fei Wang, Jian Li
  • Patent number: 10487062
    Abstract: A regioselective one-step process for the synthesis of 2-hydroxyquinoxaline of Formula (1) or tautomers thereof: comprising reacting 1,2-phenylenediamine of Formula (2): with an excess amount of glyoxylic acid, glyoxylic acid monohydrate, or a 2,2-dialkoxyacetic acid of Formula (3): at a low temperature; wherein R1 and R2 are as defined in the specification.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: November 26, 2019
    Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: Shao-Zheng Peng, Yuan-Ting Cho, Pao-Chiung Hong
  • Patent number: 10479792
    Abstract: A compound of Formula (I), or a salt thereof, compositions comprising the compound, processes for its preparation and its use in therapy, for example in the treatment of parasitic diseases such as Chagas disease, Human African Trypanosomiasis (HAT), Animal African trypanosomiasis (AAT) and leishmaniasis, particularly visceral leishmaniasis (VL).
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: November 19, 2019
    Assignees: GiaxoSmithKline Intellectual Property Development Limited, University of Dundee
    Inventors: Stephen Brand, Peter George Dodd, Eun Jung Ko, Maria Marco Martin, Timothy James Miles, Lars Henrik Sandberg, Michael George Thomas, Stephen Thompson
  • Patent number: 10472367
    Abstract: The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: November 12, 2019
    Assignees: INCYTE INCORPORATION, INCYTE HOLDINGS CORPORATION
    Inventors: Jincong Zhuo, Chunhong He, Wenqing Yao
  • Patent number: 10472342
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: November 12, 2019
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
  • Patent number: 10457655
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: October 29, 2019
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Mark J. Tebbe
  • Patent number: 10457654
    Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1—Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: October 29, 2019
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Daniel Sutherlin, Steven McKerrall, Michael Scott Wilson, Kwong Wah Lai, Philippe Bergeron, Birong Zhang, Ramsay Beveridge, Jean-Philippe Leclerc, Alexandre Lemire, Liang Zhao, Claudio Sturino
  • Patent number: 10450286
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: October 22, 2019
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
  • Patent number: 10442810
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: October 15, 2019
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
  • Patent number: 10442789
    Abstract: Provided herein are modified amino acids comprising a tetrazine groups according to Formula I: polypeptides, antibodies, payloads and conjugates comprising these modified amino acid residues derived from the modified amino acids, and methods of producing the polypeptides, antibodies, payloads and conjugates comprising the modified amino acid residues. The polypeptides, antibodies, payloads and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: October 15, 2019
    Assignee: SUTRO BIOPHARMA, INC.
    Inventors: Wenjin Yang, Qun Yin